TISSUE REGENIX GROUP PLC - ORD 0.1P
TISSUE REGENIX GROUP PLC - ORD 0.1P
Acción · GB00B5SGVL29 (XLON)
Resumen Indicadores financieros
0,32 GBP
0,63 % 0,002 GBP
Precio de cierre XLON 06.06.2025: 31,70 GBX
London (XLON) · Precios actuales y gráficos en MoneyPeak
06.06.2025 14:49

Cotizaciones actuales de TISSUE REGENIX GROUP PLC - ORD 0.1P

BolsaTickerMonedaÚltima operaciónPrecioVariación diaria
XLON: London
London
TRX.L
GBX
06.06.2025 14:49
31,70 GBX
31,10 GBX
+1,93 %

Rendimiento

Día Semana Mes 3 meses 6 meses 1 año 5 años
0,00 % -0,94 % -3,94 % -23,06 % -44,39 % -53,72 % -14,32 %

Perfil de la empresa para TISSUE REGENIX GROUP PLC - ORD 0.1P Acción

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through BioSurgery, Orthopaedics & Dental, and GBM-V & Cardiac divisions. The company provides dCELL technology, a soft tissue decellularisation process that removes DNA and cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductive to stimulate and regenerate native bone growth. In addition, the company provides DermaPure, a decellularised dermal allograft for reinforcement, repair, and replacement of damaged or inadequate integumental tissue and other homologous uses of human integument; and SurgiPure XD, Decellularised porcine dermal reconstructive tissue matrix for the repair of hernias and body wall defects. Further, it offers OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient's own cells; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedic; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company provides DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; CardioPure products; Matrix OI 100 DBM for non-structural bone-grafting; Matrix OI Strips and Blocks, a stem cell containment human scaffold; AmnioWorks for ophthalmology and wound covering; and sports medicine products. The company was incorporated in 2006 and is based in Garforth, the United Kingdom.

Datos de la empresa

Nombre TISSUE REGENIX GROUP PLC - ORD 0.1P
Empresa Tissue Regenix Group plc
Sitio web https://www.tissueregenix.com
Mercado principal XLON London
ISIN GB00B5SGVL29
Tipo de valor Acción
Sector Healthcare
Industria Biotechnology
CEO Mr. Daniel Ray Lee
Capitalización de mercado 26 Mio
País Reino Unido
Moneda GBP
Empleados 0,1 T
Dirección Unit 3, LS25 2GY Garforth
Fecha de OPV 2006-12-21

Splits de acciones

Fecha Split
28.04.2023 1:100
29.06.2010 1:5

Símbolos de cotización

Nombre Símbolo
London TRX.L

Otras acciones

Los inversores que tienen TISSUE REGENIX GROUP PLC - ORD 0.1P también tienen las siguientes acciones en su cartera:
JPM-CHINA A REI EQ D
JPM-CHINA A REI EQ D ETF
R WAT.INTL
R WAT.INTL Acción
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras. Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Aviso legal Protección de datos Blog Comunidad Comentarios Changelog
Im App Store herunterladen Bei Google Play herunterladen
Todos los derechos reservados © LCP GmbH 2025